Emergence of raltegravir-resistant HIV-1 in the central nervous system

被引：7
|
作者：
Watanabe, K. [1 ]
Honda, M. [1 ]
Watanabe, T. [1 ]
Tsukada, K. [1 ]
Teruya, K. [1 ]
Kikuchi, Y. [1 ]
Oka, S. [1 ]
Gatanaga, H. [1 ]
机构：
[1] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Shinjuku Ku, Tokyo 1628655, Japan
来源：
INTERNATIONAL JOURNAL OF STD & AIDS | 2010年 / 21卷 / 12期
关键词：
integrase; resistant; cerebrospinal fluid; Q148R; HIV; raltegravir; CEREBROSPINAL-FLUID; INFECTION;
D O I：
10.1258/ijsa.2009.009283
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Integrase inhibitor-resistant HIV-1 was detected in the cerebrospinal fluid, but not in the plasma of a 42-year-old man with HIV encephalopathy treated with a raltegravir (RAL)-containing regimen. Raltegravir resistance may develop in the central nervous system when the virus is already multi-drug resistant because of different penetration into cerebrospinal fluid of individual antiretroviral agents.
引用
收藏
页码：840 / 841
页数：2
相关论文
共 50 条
  • [21] DOCKING OF RALTEGRAVIR TO HIV-1 INTEGRASE STRUCTURE ENSEMBLE
    Wei, Caiyi
    Liu, Zeyu
    Zhang, Dawei
    Mei, Ye
    JOURNAL OF THEORETICAL & COMPUTATIONAL CHEMISTRY, 2010, 9 (06) : 1053 - 1063
  • [22] Central Nervous System Complications of HIV in Children
    Huff, Hanalise V.
    Sportiello, Kristen
    Bearden, David R.
    CURRENT HIV/AIDS REPORTS, 2024, 21 (02) : 40 - 51
  • [23] Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals
    Ceccarelli, Giancarlo
    Brenchley, Jason M.
    Cavallari, Eugenio Nelson
    Scheri, Giuseppe Corano
    Fratino, Mariangela
    Pinacchio, Claudia
    Schietroma, Ivan
    Fard, Saeid Najafi
    Scagnolari, Carolina
    Mezzaroma, Ivano
    Vullo, Vincenzo
    d'Ettorre, Gabriella
    NUTRIENTS, 2017, 9 (11):
  • [24] Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
    Nguyen, Bach-Yen T.
    Isaacs, Robin D.
    Teppler, Hedy
    Leavitt, Randi Y.
    Sklar, Peter
    Iwamoto, Marian
    Wenning, Larissa A.
    Miller, Michael D.
    Chen, Joshua
    Kemp, Ramon
    Xu, Wei
    Fromtling, Robert A.
    Vacca, Joseph P.
    Young, Steven D.
    Rowley, Michael
    Lower, Michael W.
    Gottesdiener, Keith M.
    Hazuda, Daria J.
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALIST CANDIDATES OF THE PRIX GALIEN USA, INTERNATIONAL, AND PRO BONO HUMANITARIAN AWARDS 2010, 2011, 1222 : 83 - 89
  • [25] Human Immunodeficiency Virus Type-1 (HIV-1) Transcriptional Regulation, Latency and Therapy in the Central Nervous System
    Hokello, Joseph
    Sharma, Adhikarimayum Lakhikumar
    Tyagi, Priya
    Bhushan, Alok
    Tyagi, Mudit
    VACCINES, 2021, 9 (11)
  • [26] Biochemical and Pharmacological Analyses of HIV-1 Integrase Flexible Loop Mutants Resistant to Raltegravir
    Metifiot, Mathieu
    Maddali, Kasthuraiah
    Naumova, Alena
    Zhang, Xuemin
    Marchand, Christophe
    Pommier, Yves
    BIOCHEMISTRY, 2010, 49 (17) : 3715 - 3722
  • [27] Strategies to target the central nervous system HIV reservoir
    Mastrangelo, Andrea
    Gama, Lucio
    Cinque, Paola
    CURRENT OPINION IN HIV AND AIDS, 2024, 19 (03) : 133 - 140
  • [28] The impact of HIV central nervous system persistence on pathogenesis
    Brew, Bruce J.
    Barnes, Stephanie L.
    AIDS, 2019, 33 : S113 - S121
  • [29] Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study
    Madeddu, Giordano
    Menzaghi, Barbara
    Ricci, Elena
    Carenzi, Laura
    Martinelli, Canio
    Di Biagio, Antonio
    Parruti, Giustino
    Orofino, Giancarlo
    Mura, Maria S.
    Bonfanti, Paolo
    AIDS, 2012, 26 (18) : 2412 - 2415
  • [30] HIV-1 gp120 and Drugs of Abuse: Interactions in the Central Nervous System
    Silverstein, Peter S.
    Shah, Ankit
    Weemhoff, James
    Kumar, Santosh
    Singh, D. P.
    Kumar, Anil
    CURRENT HIV RESEARCH, 2012, 10 (05) : 369 - 383
12345